KIT S501_A502INSAY

CI-VAR-00004079Explore in graph →CIViC 1206

Curated evidence

Evidence by cancer (9 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–9 of 9 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Gastrointestinal Stromal Tumor9
KIT S501_A502INSAY	Imatinib	Predictive	B	Supports Resistance	—	submitted	EID2855 Gastrointestinal stromal tumor (GIST) patients with exon 9 mutations in KIT were less likely to show a complete or partial response to imatinib (44.4% vs. 71.7%, P=0.007) and had a shorter time to tum… (full text at CIViC) PMID 20008851 · Gramza et al., 2009 · Open in CIViC	civic
KIT S501_A502INSAY	Imatinib	Predictive	B	Supports Resistance	—	submitted	EID2856 Gastrointestinal stromal tumor (GIST) patients with exon 9 mutations in KIT were less likely to show a complete or partial response to imatinib (44.4% vs. 71.7%, P=0.007) and had a shorter time to tum… (full text at CIViC) PMID 16624552 · Debiec-Rychter et al., 2006 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.